ReviewCurrent urology reports2026
Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewThis review underscores the importance of recognizing sarcomatoid features in renal cell carcinoma, as this component significantly impacts prognosis and treatment strategies. RECENT
findingsSarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of renal cancer characterized by poor prognosis and distinct biological features. Despite its clinical significance, there remains a knowledge gap regarding the comprehensive understanding of its molecular and therapeutic landscape. Recent studies provided an extensive overview of the clinical, pathological, and molecular characteristics of sRCC, highlighting its unique genomic alterations and immune profile. Notably, sRCC exhibits a highly inflamed tumor microenvironment, which correlates with increased responsiveness to immune checkpoint inhibitors. Our findings suggest that integrating immunotherapy into the management of sRCC could enhance patient outcomes, paving the way for future research and clinical applications in this challenging cancer subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.